Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Management of Pediatric Vitiligo: Early Treatment, Psychological Impact, Diagnosis, and Parent Counseling
Description
The talk reviews management of pediatric vitiligo, emphasizing that early treatment is often more effective, especially for recent-onset lesions on the face and neck, while long-standing acral areas and areas with white hairs are harder to treat. First-line therapy typically starts with topical agents such as tacrolimus or similar calcineurin inhibitors, followed by phototherapy when needed, including consideration of home handheld narrowband UVB devices for children who cannot easily attend clinic-based sessions. The speaker stresses that treatment should address not only the child but also the family’s psychological well-being, since vitiligo can cause anxiety, low self-esteem, bullying, social isolation, and activity avoidance, particularly in adolescents, girls, and those with visible or extensive disease. Screening for associated issues such as thyroid disease and vitamin D deficiency is recommended. Clear counseling is important to set realistic expectations: stabilization may be a goal, repigmentation takes months, and parents need guidance about adherence and safe, evidence-based care. The talk also highlights diagnostic challenges and frequent misdiagnosis, noting the usefulness of Wood’s lamp and the need to distinguish vitiligo from conditions such as giant nevus depigmentosus. Finally, it warns against harmful alternative remedies, encourages referral to support organizations and educational resources, and underscores the importance of early, compassionate, and family-centered care.
View moreConclusions
- Early diagnosis and early treatment of pediatric vitiligo are associated with better repigmentation outcomes and may help slow disease progression.
- Topical therapies are generally first-line, with tacrolimus or similar calcineurin inhibitors often used before escalating to phototherapy or other specialist treatments.
- Children with recent-onset, facial or neck vitiligo tend to respond better to treatment, while acral, longstanding, or white-haired lesions are more resistant.
- Vitiligo has major psychological and social effects in children and their families, so management should address anxiety, self-esteem, bullying, and parental distress as well as skin changes.
- Many children and parents need realistic expectations that vitiligo usually requires months of treatment and that stabilization, not complete cure, is often the immediate goal.
- Delays in diagnosis and treatment are common, and a substantial proportion of patients receive no vitiligo-specific therapy for long periods after diagnosis.
- A notable number of untreated patients receive antidepressants or anxiolytics, suggesting that inadequate vitiligo care may contribute to psychological burden.
- Risk of severe psychosocial impact is higher in adolescents, females, and patients with visible or extensive disease.
- Vitiligo appears to be more common in some ethnic minority groups, including Asian and Black populations, than in White populations in the UK data presented.
- Misdiagnosis is frequent, so careful differential diagnosis and use of tools such as Wood’s lamp are important, especially for conditions like nevus depigmentosus.
- General workup should include screening for thyroid disease and considering vitamin D deficiency, particularly in children with limited sun exposure.
- Education is essential to counter harmful myths and unsafe alternative treatments, which can lead to injury and delayed proper care.
- Patient organizations and supportive resources can help children cope with stigma and communicate about vitiligo in school and social settings.
- Overall, effective pediatric vitiligo care must combine medical treatment, diagnostic accuracy, psychosocial support, family education, and long-term follow-up.
- Eleftheriadou V, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022, 186:18-29.#10.1111/bjd.20596
- Senteschal J, et al. J Eur Acad Dermatol Venereol, 2023;37:2185-2195.
- Ezzedine K, Eleftheriadou V, Jones H, Bibea K, Kuo FI, Sturm D, Pandya AG. Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol. 2021 Nov;22(6):757-774.#10.1007/s40257-021-00631-6
- Bhattacharyya A, Somasundaram A, Biswas S. A giant white macule since birth – Uncommon presentation of a common entity. CosmoDerma. 2023;3:186.#10.25259/csdm_240_2023
- Guerra L, Dellambra E, Brescia S, Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 2010 Jun 1;11(5):451-67.#10.2174/138920010791526105